Paritaprevir
Paritaprevir (previously known as ABT-450) is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.

Paritaprevir was a component of Viekira Pak and Technivie. In May 2018, the FDA announced that Technivie and Viekira were to be discontinued. The discontinuation was voluntary and not related to the safety, quality, or efficacy of the medicine. It was estimated that both medications would be available until January 1, 2019.
Q83141645
NS3
UNK
Q6955244
4A
MISC
Q87324999
serine protease
Concept
Q306764
Abbott Laboratories
ORG
Q154869
hepatitis C
Concept
Q422618
ritonavir
Concept
Q421862
ribavirin
Concept
Q708693
hepatitis C virus
Concept
Q616005
binding site
Concept
Q19858657
Viekira Pak
Concept
Q16824572
Paritaprevir
MISC
Q16824572
Paritaprevir
MISC
2018-05-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
May 2018
DATE
2019-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
January 1, 2019
DATE
-450^^http://www.w3.org/2001/XMLSchema#decimal
-450
NUMBER
+3^^http://www.w3.org/2001/XMLSchema#decimal
3
NUMBER
-4^^http://www.w3.org/2001/XMLSchema#decimal
-4
NUMBER
+12^^http://www.w3.org/2001/XMLSchema#decimal
12
NUMBER
+24^^http://www.w3.org/2001/XMLSchema#decimal
24
NUMBER
+95^^http://www.w3.org/2001/XMLSchema#decimal
95
NUMBER
+1^^http://www.w3.org/2001/XMLSchema#decimal
1
NUMBER
+3^^http://www.w3.org/2001/XMLSchema#decimal
3
NUMBER
medical condition treated
medical condition treated
has cause
part of